ERBB2 and breast cancer: From a clinical perspective, breast cancer subtyping relies on immunohistochemical (IHC) analysis of critical biomarkers, including estrogen and progesterone receptors (ER and PR), the proliferation index Ki-67, and human epidermal growth factor receptor 2 (HER2) [72].